These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12580110)

  • 1. [Application of an artificial neural network in the design of sustained-release dosage forms].
    Wei XH; Wu JJ; Liang WQ
    Yao Xue Xue Bao; 2001 Sep; 36(9):690-4. PubMed ID: 12580110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of an artificial neural network and pharmacokinetic simulations in the design of controlled-release dosage forms.
    Chen Y; McCall TW; Baichwal AR; Meyer MC
    J Control Release; 1999 May; 59(1):33-41. PubMed ID: 10210720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of metformin HCl 500 mg sustained release matrix tablets using Artificial Neural Network (ANN) based on Multilayer Perceptrons (MLP) model.
    Mandal U; Gowda V; Ghosh A; Bose A; Bhaumik U; Chatterjee B; Pal TK
    Chem Pharm Bull (Tokyo); 2008 Feb; 56(2):150-5. PubMed ID: 18239298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation.
    Huang YB; Tsai YH; Yang WC; Chang JS; Wu PC; Takayama K
    Eur J Pharm Biopharm; 2004 Nov; 58(3):607-14. PubMed ID: 15451535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Release of diltiazem chloride and ibuprofen from hydrophilic matrix tablets].
    Vostalová L; Rabisková M; Medvecká G
    Ceska Slov Farm; 2003 Nov; 52(6):295-8. PubMed ID: 14661369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four artificial neural network software programs used to predict the in vitro dissolution of controlled-release tablets.
    Chen Y; Jiao T; McCall TW; Baichwal AR; Meyer MC
    Pharm Dev Technol; 2002; 7(3):373-9. PubMed ID: 12229268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of controlled release tablet performance and hydrogel strength on in vitro/in vivo correlation.
    Roshdy MN; Schnaare RL; Sugita ET; Schwartz JB
    Pharm Dev Technol; 2002 May; 7(2):155-68. PubMed ID: 12066571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preparation of diltiazem hydrochloride delayed-onset, sustained release tablet].
    Zhang N; Zhu JB
    Yao Xue Xue Bao; 2002 Sep; 37(9):724-7. PubMed ID: 12567900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of binary polymer system in drug release rate modulation. 2. Influence of formulation variables and hydrodynamic conditions on release kinetics.
    Kim H; Fassihi R
    J Pharm Sci; 1997 Mar; 86(3):323-8. PubMed ID: 9050800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of similarity factor in development of controlled-release diltiazem tablet.
    Peh KK; Wong CF
    Drug Dev Ind Pharm; 2000 Jul; 26(7):723-30. PubMed ID: 10872090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies in release behavior of diltiazem HCl from matrix tablets containing (hydroxypropyl)methyl cellulose and xanthan gum.
    Gohel MC; Amin AF; Patel KV; Panchal MK
    Boll Chim Farm; 2002; 141(1):21-8. PubMed ID: 12064053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral mucosal bioadhesive tablets of pectin and HPMC: in vitro and in vivo evaluation.
    Miyazaki S; Kawasaki N; Nakamura T; Iwatsu M; Hou WM; Attwood D
    Int J Pharm; 2000 Aug; 204(1-2):127-32. PubMed ID: 11011995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms.
    Maggi L; Bruni R; Conte U
    Int J Pharm; 2000 Feb; 195(1-2):229-38. PubMed ID: 10675700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of buccoadhesive propranolol hydrochloride tablet formulations: effect of fillers.
    Akbari J; Nokhodchi A; Farid D; Adrangui M; Siahi-Shadbad MR; Saeedi M
    Farmaco; 2004 Feb; 59(2):155-61. PubMed ID: 14871508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro and in-vivo studies of the diclofenac sodium controlled-release matrix tablets.
    Liu CH; Kao YH; Chen SC; Sokoloski TD; Sheu MT
    J Pharm Pharmacol; 1995 May; 47(5):360-4. PubMed ID: 7494183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Artificial neural network parameters optimization software and its application in the design of sustained release tablets].
    Zhang XY; Chen DW; Jin J; Lu W
    Yao Xue Xue Bao; 2009 Oct; 44(10):1159-64. PubMed ID: 20055142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation of biphasic release tablets containing slightly soluble drugs.
    Maggi L; Machiste EO; Torre ML; Conte U
    Eur J Pharm Biopharm; 1999 Jul; 48(1):37-42. PubMed ID: 10477326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of Melatonin Dissolution from Extended Release Matrices Using Artificial Neural Networking.
    Martarelli D; Casettari L; Shalaby KS; Soliman ME; Cespi M; Bonacucina G; Fagioli L; Perinelli DR; Lam JK; Palmieri GF
    Curr Drug Deliv; 2016; 13(4):565-73. PubMed ID: 26051184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.
    Cao QR; Choi YW; Cui JH; Lee BJ
    J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug.
    Wei Z; Yu Z; Bi D
    Drug Dev Ind Pharm; 2001 May; 27(5):469-74. PubMed ID: 11448055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.